Principia is a biopharmaceutical company that develops small molecule drugs for the treatment of immune-mediated diseases.
Read more
President & CEO
Martin Babler
Innovimmune Biotherapeutics is seen as one of Principia Biopharma, Inc.'s top competitors. Innovimmune Biotherapeutics's headquarters is in New York, New York, and was founded in 2010. Like Principia Biopharma, Inc., Innovimmune Biotherapeutics also works within the Biotechnology industry. Innovimmune Biotherapeutics generates 50% of Principia Biopharma, Inc.'s revenue.
ASLAN Pharmaceuticals is one of Principia Biopharma, Inc.'s top rivals. ASLAN Pharmaceuticals was founded in 2010, and its headquarters is in Singapore, Central Singapore. Like Principia Biopharma, Inc., ASLAN Pharmaceuticals also works within the Biotechnology field. ASLAN Pharmaceuticals has 51 fewer employees than Principia Biopharma, Inc..
Clovis Oncology is Principia Biopharma, Inc.'s #3 rival. Clovis Oncology is a Public company that was founded in 2009 in Boulder, Colorado. Like Principia Biopharma, Inc., Clovis Oncology also competes in the Biotechnology sector. Compared to Principia Biopharma, Inc., Clovis Oncology has 360 more employees.
June 23, 2021
MarketScreener
June 24, 2021
centralcharts
June 24, 2021
CompanyNews HQ
Annual Revenue
$20M
Principia Biopharma, Inc.'s revenue is the ranked 13th among it's top 10 competitors. The top 10 competitors average 10.7B. Over the last two quarters, Principia Biopharma, Inc.'s revenue has grown by 66.7%. Specifically, in Q2 2020's revenue was $50M; in Q2 2019, it was $30M.
No recent acquisitions found related to Principia Biopharma, Inc.
Since Principia Biopharma, Inc. was founded in 2008, it has participated in 6 rounds of funding. In total Principia Biopharma, Inc. has raised $246.2M. Principia Biopharma, Inc.'s last funding round was on Sep 2018 for a total of $106.2M
Since Principia Biopharma, Inc. was founded in 2008, it has participated in 6 rounds of funding. In total Principia Biopharma, Inc. has raised $246.2M. Principia Biopharma, Inc.'s last funding round was on Sep 2018 for a total of $106.2M
No recent investments found related to Principia Biopharma, Inc.
